Immediate Impact
2 from Science/Nature 51 standout
Citing Papers
The interaction of innate immune and adaptive immune system
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Grant Langdon being referenced
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
2020
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Grant Langdon | 288 | 135 | 164 | 24 | 703 | |
| Carol Braun Trapnell | 200 | 38 | 160 | 23 | 691 | |
| Elodie Gautier‐Veyret | 232 | 121 | 162 | 38 | 626 | |
| Sarah Allegra | 242 | 64 | 200 | 56 | 766 | |
| Ying Wu | 224 | 166 | 148 | 32 | 817 | |
| Keith Nieforth | 210 | 43 | 241 | 29 | 770 | |
| Sam Liao | 58 | 95 | 134 | 26 | 677 | |
| Anne Paccaly | 235 | 33 | 170 | 35 | 811 | |
| Naofumi Suyama | 93 | 75 | 216 | 43 | 640 | |
| Bindu Murthy | 78 | 134 | 58 | 40 | 635 | |
| Julie Smet | 76 | 91 | 127 | 27 | 657 |
All Works
Loading papers...